Generic Cymbalta Approved
Title: Generic Cymbalta ApprovedCategory: Health NewsCreated: 12/11/2013 7:36:00 PMLast Editorial Review: 12/12/2013 12:00:00 AM (Source: MedicineNet Depression General)
Source: MedicineNet Depression General - December 12, 2013 Category: Psychiatry Source Type: news
Several Indian companies get FDA nod for anti-depressant drug
The US Food and Drug Administration has approved the first generic versions of Cymbalta, a prescription medicine used in treatment of depression. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 12, 2013 Category: Pharmaceuticals Source Type: news
Generic Cymbalta Approved (FREE)
By the Editors
The FDA has approved generic versions of the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 12, 2013 Category: Primary Care Source Type: news
FDA Okays First Cymbalta GenericsFDA Okays First Cymbalta Generics
The FDA has approved the first generic versions of the antidepressant Cymbalta. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2013 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news
FDA approves generics of Lilly antidepressant Cymbalta
(Reuters) - The U.S. Food and Drug Administration on Wednesday approved generic versions of Eli Lilly and Co's antidepressant Cymbalta, the U.S. drugmaker's biggest-selling product. (Source: Reuters: Health)
Source: Reuters: Health - December 11, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
FDA approves first generic versions of antidepressant drug Cymbalta
The U.S. Food and Drug Administration today approved the first generic versions of Cymbalta (duloxetine delayed-release capsules), a prescription medicine used to treat depression and other conditions. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 11, 2013 Category: American Health Source Type: news
A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose - Taylor D, Lenox-Smith A, Bradley A.
Depression and anxiety disorders are among the most common disorders treated by general practitioners (GPs) in the UK. Since both disorders are associated with a significantly increased risk of suicide, including with antidepressant overdose, the safety of... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - November 15, 2013 Category: Global & Universal Tags: Poisoning Source Type: news
Duloxetine Prophylaxis for Episodic MigraineDuloxetine Prophylaxis for Episodic Migraine
Could the SNRI duloxetine be effective for the prevention of migraine? Headache (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2013 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Dr. Timothy J. Garnett
Chief Medical Officer & SVP, Eli Lilly & CompanyDr. Timothy Garnett, FRCOG, MFFP, FFPM, is Chief Medical Officer, Senior Vice-President and Co-Leader of the Development Center of Excellence managing Medical Affairs, Global Health Outcomes, Regulatory, Safety and Translational Medicine/Pharmacogenomics for Eli Lilly and Company. During his 14 years at Lilly, Dr. Garnett has served as Vice President for Global Patient Safety; Global Brand Development Leader and Group Medical Director responsible for the development of Duloxetine for incontinence, pain and depression; Medical Director Duloxetine SUI Team; and European...
Source: PHRMA - November 5, 2013 Category: Pharmaceuticals Authors: Leah Source Type: news
Dr. Timothy J. Garnett, FRCOG, MFFP, FFPM
Chief Medical Officer & SVP, Development Center of Excellence, Eli Lilly & CompanyDr. Timothy Garnett, FRCOG, MFFP, FFPM, is Chief Medical Officer, Senior Vice-President and Co-Leader of the Development Center of Excellence managing Medical Affairs, Global Health Outcomes, Regulatory, Safety and Translational Medicine/Pharmacogenomics for Eli Lilly and Company. During his 14 years at Lilly, Dr. Garnett has served as Vice President for Global Patient Safety; Global Brand Development Leader and Group Medical Director responsible for the development of Duloxetine for incontinence, pain and depression; Medical Director...
Source: PHRMA - November 5, 2013 Category: Pharmaceuticals Authors: Leah Source Type: news
Lilly beats forecast, cuts costs before Cymbalta fades
(Reuters) - Eli Lilly and Co reported higher-than-expected quarterly earnings on Wednesday as it slashed costs ahead of generic competition later this year for its biggest product, antidepressant Cymbalta, and raised its 2013 profit view on plans for more streamlining. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Lilly beats forecast, helped by soon-fading Cymbalta
(Reuters) - Eli Lilly and Co reported higher-than-expected quarterly earnings, helped by cost cuts and strong sales of Cymbalta, a depression treatment that will lose patent protection by year end, and the drugmaker raised its full-year profit forecast. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Eli Lilly Freezes Salaries as Patents Expire
Eli Lilly and Company is freezing salaries for most employees in 2014 to reduce costs. Officials said the company would also reduce bonuses paid out in 2015 for 2014 employee performances.
"This is a difficult, but necessary decision. While we remain confident in our future, we continue to face the most significant challenges in our history. We expect to lose about 20 percent of our global revenue in 2014 because of the expiration of the Cymbalta and Evista patents in the U.S. While we've taken many actions to reduce costs and become a leaner organization, we must do more. We estimate these actions will enable us to save...
Source: PharmaManufacturing.com - July 18, 2013 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: news
Cymbalta Side Effects (Duloxetine)
Cymbalta (duloxetine) is an antidepressant medication that is also used to treat diabetic neuropathy. It is classed as an SNRI - Serotonin-Norepinephrine Reuptake Inhibitor. It is used to treat depressive symptoms including the aches and pains that can be caused by depression. This page lists the best-known Cymbalta side effects. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - July 4, 2013 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news
Understanding Stress Incontinence
Stress incontinence is one of the most common forms of incontinence and it’s estimated that three million people in the UK are affected although this number may be conservative because some won’t mention it to their doctors. It also becomes more common in women as they age and go through the menopause. Estimates suggest that 1 in 5 women over 40 may suffer some degree of stress incontinence.
As we eat and drink the kidneys produce urine which passes through the ureter tubes to the bladder. The amount we eat and drink influences the amount of urine that is made. As the bladder fills with urine it swells until we feel a ...
Source: The Hysterectomy Association - May 23, 2013 Category: OBGYN Authors: Linda Parkinson-Hardman Tags: Health incontinence kegel exercises pelvic floor exercises Source Type: news
